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but no pairwise comparisons were statistically significant. CONCLUSIONS: The 
analysis demonstrates that many of the treatments are efficacious in controlling 
symptoms, although side effects resulting from treatment should be considered; 
weight gain is commonly observed, and treatment discontinuation due to adverse 
events is variable between studies. The lack of high-quality studies in this popula-
tion highlights a need for further research.
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OBJECTIVES: To assess relative efficacy and tolerability of vortioxetine versus other 
antidepressants in patients with major depressive disorder (MDD) who experience 
inadequate response after treatment with selective serotonin reuptake inhibitors 
(SSRIs) or serotonin–norepinephrine reuptake inhibitors (SNRIs). METHODS: A 
systematic literature review identified 27 switch studies, three of which (REVIVE, 
Kasper 2013 and STAR*D) contributed to the relevant network for quantitative 
assessment, based on remission rate and withdrawal rate due to adverse events 
(AEs). Switch treatments compared to vortioxetine in the analysis were agomel-
atine, sertraline, venlafaxine XR and bupropion SR, commonly used in clinical 
practice. Simple adjusted indirect comparisons using Bucher’s method were also 
conducted, in line with guidelines from EUnetHTA. RESULTS: Direct analysis of 
remission rates based on the REVIVE study showed vortioxetine had a signifi-
cantly higher remission rate (relative difference: -11.0% [95% CI: -19.4; -2.6]) than 
agomelatine. Indirect comparisons revealed that vortioxetine had numerically 
higher remission rates than sertraline (relative difference: -14.4%, [95% CI: -29.9; 
1.1]), venlafaxine (relative difference: -7.20%, [95% CI: -24.3; 9.9]), and bupropion 
(relative difference: -10.70%, [95% CI: -27.8; 6.4]). Rate of withdrawals due to AE 
was numerically lower with vortioxetine than agomelatine (relative difference: 
3.6%, [95% CI: -1.1; 8.3]). Indirect comparison showed that withdrawal rates due 
to AE were significantly lower for vortioxetine than sertraline (relative difference: 
12.1%, [95% CI: 3.1; 21.1]), venlafaxine (relative difference: 12.3%, [95% CI: 0.8; 23.8]), 
and bupropion (relative difference: 18.3%, [95% CI: 6.4; 30.1]). CONCLUSIONS: The 
evidence supporting treatment strategies for patients with MDD with inadequate 
response to SSRI or SNRI is limited. This study demonstrates that remission rates 
for vortioxetine are numerically higher than other antidepressants widely used 
in clinical practice. Vortioxetine is a well-tolerated treatment, showing statisti-
cally lower withdrawal rates due to AE in patients with MDD with an inadequate 
response to prior SSRI or SNRI monotherapy.
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OBJECTIVES: To assess the effects of the reformulation of OxyContin (ERO) with 
physicochemical abuse-deterrent properties that are intended to make tablets 
harder to crush, dissolve or chew on rates of abuse of ERO compared to other opioids 
using 6 national surveillance systems at 3 years after reformulation. METHODS: 
Data from 6 surveillance systems were examined: 1) National Poison Data System 
(NPDS), 2) RADARS Poison Center(PC) Program, 3) NAVIPPRO ASI-MV System assess-
ing individuals in substance abuse treatment, 4) RADARS Drug Diversion program 
using law enforcement officials’ surveillance,5) doctor-shopping using the IMS 
prescription database, and 6) Spontaneous adverse event reports of fatalities to 
the manufacturer. Changes in abuse rates were compared from the year before (Jul 
2009-Jun 2010) to 3 years after (January 2011 - June 2013) reformulation of ERO. The 
period from July to December 2010 was considered a transition period. Comparator 
opioid groups were: a) other extended-release opioid analgesic tablets and capsules 
(excluding ERO, methadone and transdermal patches) and b) immediate-release 
oxycodone (single-entity and combination products). RESULTS: Compared to the 
year prior to reformulation, there were large decreases in abuse rates of ERO in 
all 6 surveillance systems in the 3 years after ERO reformulation: 55% decrease 
(p< 0.001) in NPDS, 55% decrease (p< 0.001) in RADARS PC, 48% decrease (p< 0.001) in 
NAVIPPRO System assessing individuals in substance abuse treatment, 61% decrease 
(p< 0.001) in RADARS Drug Diversion program using law enforcement officials’ sur-
veillance, 50% decrease in doctor shopping rates for ERO nationally. Reductions 
for ERO were significantly greater than changes for the two comparator opioid 
groups. Spontaneously reported overdose fatalities reported to the manufacturer 
decreased 87% by the 3rdyear, while non-fatal ERO reports did not decrease post-
reformulation. CONCLUSIONS: These findings indicate that abuse of ERO declined 
after its reformulation and these declines have persisted through three years post-
reformulation. Additional follow-up is ongoing.
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OBJECTIVES: Despite different pharmacological strategies in the management of 
depression, many patients experience inadequate response to treatment in clinical 
practice. A systematic review was carried out to perform a qualitative assessment 
of studies examining different antidepressant monotherapies in patients with 
major depressive disorder (MDD), and an inadequate response to prior selective-
serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor 
(SNRI) therapy. METHODS: MEDLINE®, Embase®, Cochrane, CDSR, and PsychINFO® 
databases, and clinical trial registries were searched from January 1980 to 27 March 
2014. The review included trials in patients with MDD with inadequate response to 
SSRIs/SNRIs. Included studies underwent a two-stage screening process conducted 
by two independent reviewers, with discrepancies reconciled by a third independent 
reviewer. Data were extracted by a single reviewer with quality check performed by 
another, and multiple publications were linked. The quality of included studies was 
critically appraised based on recommendations from national guidelines. RESULTS: 
The database search retrieved 11 953 citations, of which 27 randomized controlled 
trials from 54 publications met the inclusion criteria. The switch interventions 
assessed included: SSRIs, SNRIs, and other non-SSRI/SNRI antidepressants such as 
monoamine oxidase inhibitors, tricyclic antidepressants, tetracyclic antidepres-
sants, with a few studies comparing different antidepressants in switch therapy. 
The evidence varied in terms of: type of treatment, study duration (ranging from 
2 weeks to 14 weeks), depression scale, sample size (< 100 to > 500 patients), prior 
therapy, and definition of inadequate response. Generally, the mean age of included 
patients was comparable (44 years to 48 years). Overall, few of the included studies 
were deemed to be of good quality. CONCLUSIONS: A comprehensive overview of 
switch studies assessing antidepressant monotherapies in prior SSRI/SNRI non-
responding patients found an overall low strength of evidence for studies evaluating 
these monotherapies. Limited clinical data have been retrieved but give the pos-
sibility to perform further quantitative evaluations.
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OBJECTIVES: Paroxetine has strong anticholinergic properties and may lead to 
adverse cognitive outcomes. This study compared paroxetine and other selective 
serotonin reuptake inhibitors (SSRIs) with respect to cognition among elderly nurs-
ing home residents with depression. METHODS: A propensity score-adjusted retro-
spective cohort study was conducted using data from Medicare Part D claims and 
Minimum Data Set (MDS) from 2007-2010. New users of paroxetine and other SSRIs 
were followed until they reached the end of the follow up period (1 year), switched 
to a different antidepressant class, used psychotherapy, had a gap or more than 15 
days in the use of index antidepressant class, whichever occurred earlier. Exposure 
to SSRIs formed the main independent variable. The main outcome variable was 
cognition and it was measured using the MDS Cognition Scale. Repeated measures 
mixed model was used to examine the effect of SSRIs use on cognition, with use of 
other SSRIs as the reference category. Other covariates in the final model included 
propensity scores and their interaction terms. RESULTS: The study cohort consisted 
of 1,081 elderly nursing home residents. Of these, 63 (5.83%) received paroxetine 
and 1,018 received other SSRIs (94.17%). After adjusting for propensity scores, the 
repeated measure mixed model did not find any statistically significant difference in 
cognition with the use of paroxetine (β = -0.25 [95% CI, -0.84, 0.35]) when compared 
to other SSRIs. Results from the sensitivity analysis were consistent with the main 
findings. CONCLUSIONS: This study did not find any significant effect of paroxetine 
on cognition when compared to other SSRIs in elderly nursing home residents with 
depression. Long term studies are needed to evaluate comparative safety profiles 
of SSRIs in this vulnerable population.
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OBJECTIVES: Women are diagnosed with depression twice as often as men. 
Concerning self-reported depression though, gender differences are not that dis-
tinct. Prescription of antidepressants (ADs) has increased considerably the past 
decades, especially for women. This study aimed to examine gender differences in 
self-reported depression and the relation to prescribed ADs and also in the prescrip-
tion of various types of ADs. METHODS: Data from the population-based cross-sec-
tional survey “Public Health in Sweden 2012” was used (n= 16,000 aged 18-84 years, 
response rate 49.3%). Symptoms of depression were measured with the Hospital 
Anxiety Depression Scale (HADS, cut-off score ≥ 8). Self-reported use of ADs two 
weeks prior to receiving the questionnaire was supplemented with prescription data 
(ATC-codes) from the national Swedish Prescribed Drug Register. RESULTS: Men and 
women reported depression to similar extent (men 12.3%, women 11.2%). However, 
women were more often prescribed ADs compared to men (men 3.7%, women 6.8%; 
p< 0.0001). Nine per cent of all women in the study population reported depression 
but had no AD treatment, 2.1% reporting depression and used ADs, and 4.7% used 
ADs but reported no depression. The corresponding figures for men were 10.8%, 1.5% 
and 2.2% (p< 0.0001). Selective serotonin reuptake inhibitors (SSRIs, N06AB) were the 
most commonly prescribed ADs for both men (74.8%) and women (79.2%). As for the 
SSRIs, no statistical significant gender difference was found for the tricyclic antide-
pressants (TCAs, N06AA; men 9.5%, women 6.7%). However, men were prescribed 
“Other ADs” (N06AX) significantly more often than women (men 43.3%, women 
29.2%; p< 0.005). CONCLUSIONS: Although women and men reported depression 
to similar extent, women were prescribed ADs almost twice as often as men. Also, 
women used ADs without being currently depressed more often than men. Further, 
men were prescribed “Other ADs” more frequently than women.
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